Causes, Incidence, and Risk Factors of CLL
CLL is the second most common form of leukemia affecting adults in the United States, with approximately 10,000 new cases annually.5 CLL occurs more often in men than in women and is most often diagnosed in older adults.6
CLL is the result of an error within the DNA or genetic material of a single lymphocyte-forming cell that makes the cell become cancerous. How this occurs and why the body does not get rid of this defective cell is still unknown.2 However, certain people have been shown to have a greater risk for CLL.
Older people are most vulnerable to CLL, as it usually occurs in those aged 55 years and older.6 Unlike other leukemias, CLL has not been shown to be linked to exposure to radiation or cancer-causing chemicals.
In America, there is not much difference between the rates of CLL in the Caucasian and African American populations, but those of Chinese, Japanese, Filipino, Hispanic, and Native American origin are much less likely to develop CLL.6
First-degree relatives of patients are somewhat more likely to get the disease than the general population.7 This suggests that, at least in some cases, there is an inherited predisposition to develop CLL.
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].
Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.
Please see Full Prescribing Information (PDF).